scispace - formally typeset
A

Anne Kleijn

Researcher at Erasmus University Rotterdam

Publications -  17
Citations -  584

Anne Kleijn is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Oncolytic virus & Glioma. The author has an hindex of 10, co-authored 14 publications receiving 450 citations. Previous affiliations of Anne Kleijn include University of Southern California & Children's Hospital Los Angeles.

Papers
More filters
Journal ArticleDOI

Delta-24-RGD Oncolytic Adenovirus Elicits Anti-Glioma Immunity in an Immunocompetent Mouse Model

TL;DR: It is demonstrated that Delta-24-RGD induces anti-glioma immunity and offers the first evidence that viral infection directly enhances presentation of tumor-associated antigens to immune cells.
Journal ArticleDOI

The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.

TL;DR: Delta24-RGD treatment led to long-term survival in 50% of mice and this effect was completely lost upon administration of the immunosuppressive agent dexamethasone, providing evidence that the immune system plays a vital role in the therapeutic efficacy of oncolytic adenovirus therapy of glioma.
Journal ArticleDOI

Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules

TL;DR: SF cultures are derived from a subset of parental tumors with a shared molecular background including enrichment for extracellular matrix-associated gene modules, which provides leads to develop enhanced culture protocols for glioma samples not propagatable under current SF conditions.
Journal ArticleDOI

Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment

TL;DR: It is demonstrated that local Delta24-RGD therapy may provide a therapeutic tool to promote a prolonged shift in the protumoral M2 macrophages toward M1 in human GBM, inducing a pro-inflammatory and potentially tumor-detrimental microenvironment.